CopenHeart IE - Integrated Rehabilitation of Patients Treated for Infective Endocarditis
Launched by RIGSHOSPITALET, DENMARK · Jan 14, 2012
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Infective endocarditis (IE) is among the most serious infectious diseases in the western world. Treatment requires lengthy hospitalization, high dosage antibiotics and possible valve replacement surgery. Studies indicate that patients experience persisting physical symptoms, diminished quality of life and difficulties returning to work, up to a year post-discharge. No studies investigating the effect of, interventions aimed at relieving these problems, have been published.
A randomized clinical trial is conducted to investigate the effect and meaning of an integrated rehabilitation program...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients:
- • treated for leftsided- (native- or prosthetic valve) or cardiac device endocarditis based on Duke Criteria
- • 18 years or older
- • speaking and understanding Danish
- • providing written informed consent
- Exclusion Criteria:
- Patients:
- • unable to understand study instructions
- • with an ischemic event within the past 6 months
- • who are pregnant or breastfeeding
- • with reduced ability to follow the planned programme due to i.e. substance abuse problems or other somatic illness
- • with considerable illness in the musculoskeletal system or with physical disability, which complicates exercise training
- • whose physician advise against participation
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Trine B Rasmussen, PhD fellow
Principal Investigator
Copenhagen University Hospital Rigshospitalet, University Hospital Gentofte
Selina K Berg, MScN, Ph.d.
Principal Investigator
Copenhagen University Hospital Rigshospitalet, University Hospital Gentofte
Ann-Dorthe Zwisler, MD, Ph.d.
Principal Investigator
Copenhagen University Hospital Rigshospitalet, National Institute of Public Health, University of Southern Denmark
Henning Bundgaard, MD, Ph.d.
Principal Investigator
Rigshospitalet, Denmark
Philip Moons, Prof, PhD
Principal Investigator
Centre for Health Services and Nursing Research, KU Leuven-University of
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials